select a format

Single User License
USD 2000 INR 129580
Site License
USD 4000 INR 259160
Corporate User License
USD 6000 INR 388740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Ornithine-Transcarbamylase Deficiency-Pipeline Review, H2 2016

Ornithine-Transcarbamylase Deficiency-Pipeline Review, H2 2016


  • Products Id :- GMDHC8902IDB
  • |
  • Pages: 37
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Ornithine-Transcarbamylase Deficiency-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ornithine-Transcarbamylase Deficiency-Pipeline Review, H2 2016, provides an overview of the Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline landscape.

Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC). OTC plays an important role in the break down and removal of nitrogen the body (urea cycle). The lack of the OTC enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia), in the blood. Symptoms include vomiting, refusal to eat, progressive lethargy, and coma. Treatment includes nitrogen scavenging agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ornithine-Transcarbamylase Deficiency-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ornithine-Transcarbamylase Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ornithine-Transcarbamylase Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 3 respectively.

Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ornithine-Transcarbamylase Deficiency (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Ornithine-Transcarbamylase Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ornithine-Transcarbamylase Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ornithine-Transcarbamylase Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ornithine-Transcarbamylase Deficiency (Genetic Disorders)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ornithine-Transcarbamylase Deficiency (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Ornithine-Transcarbamylase Deficiency Overview 6

Therapeutics Development 7

Pipeline Products for Ornithine-Transcarbamylase Deficiency-Overview 7

Ornithine-Transcarbamylase Deficiency-Therapeutics under Development by Companies 8

Ornithine-Transcarbamylase Deficiency-Pipeline Products Glance 9

Late Stage Products 9

Early Stage Products 10

Ornithine-Transcarbamylase Deficiency-Products under Development by Companies 11

Ornithine-Transcarbamylase Deficiency-Companies Involved in Therapeutics Development 12

Dimension Therapeutics Inc 12

Lucane Pharma SA 13

PhaseRx Inc 14

Promethera Biosciences SA 15

Unicyte AG 16

Ornithine-Transcarbamylase Deficiency-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Drug Profiles 24

Cell Therapy for Urea Cycle Disorders and Liver Failure-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DTX-301-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

HepaStem-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

PRX-OTC-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

sodium benzoate-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Ornithine-Transcarbamylase Deficiency-Dormant Projects 34

Ornithine-Transcarbamylase Deficiency-Product Development Milestones 35

Featured News & Press Releases 35

Nov 28, 2016: PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Figures

Number of Products under Development for Ornithine-Transcarbamylase Deficiency, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Types, H2 2016 22

List of Tables

Number of Products under Development for Ornithine-Transcarbamylase Deficiency, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Ornithine-Transcarbamylase Deficiency-Pipeline by Dimension Therapeutics Inc, H2 2016 12

Ornithine-Transcarbamylase Deficiency-Pipeline by Lucane Pharma SA, H2 2016 13

Ornithine-Transcarbamylase Deficiency-Pipeline by PhaseRx Inc, H2 2016 14

Ornithine-Transcarbamylase Deficiency-Pipeline by Promethera Biosciences SA, H2 2016 15

Ornithine-Transcarbamylase Deficiency-Pipeline by Unicyte AG, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Ornithine-Transcarbamylase Deficiency-Dormant Projects, H2 2016 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Dimension Therapeutics Inc, Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Unicyte AG

Ornithine-Transcarbamylase Deficiency Therapeutic Products under Development, Key Players in Ornithine-Transcarbamylase Deficiency Therapeutics, Ornithine-Transcarbamylase Deficiency Pipeline Overview, Ornithine-Transcarbamylase Deficiency Pipeline, Ornithine-Transcarbamylase Deficiency Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com